Novo Nordisk A/S (NYSE:NVO) Stock Holdings Cut by Perigon Wealth Management LLC

Perigon Wealth Management LLC cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 15,314 shares of the company’s stock after selling 3,318 shares during the quarter. Perigon Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,272,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Patrick M Sweeney & Associates Inc. grew its holdings in Novo Nordisk A/S by 81.2% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company’s stock worth $960,000 after acquiring an additional 5,000 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Griffin Asset Management Inc. raised its holdings in shares of Novo Nordisk A/S by 2.3% in the 4th quarter. Griffin Asset Management Inc. now owns 8,450 shares of the company’s stock worth $727,000 after purchasing an additional 190 shares in the last quarter. Vantage Investment Partners LLC lifted its stake in Novo Nordisk A/S by 35.4% during the fourth quarter. Vantage Investment Partners LLC now owns 580,417 shares of the company’s stock valued at $49,927,000 after purchasing an additional 151,620 shares during the last quarter. Finally, Diamant Asset Management Inc. boosted its holdings in Novo Nordisk A/S by 49.4% during the fourth quarter. Diamant Asset Management Inc. now owns 23,700 shares of the company’s stock worth $2,039,000 after buying an additional 7,835 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 1.5 %

NYSE:NVO opened at $85.33 on Friday. The business’s fifty day moving average price is $94.32 and its 200 day moving average price is $113.82. The firm has a market capitalization of $382.91 billion, a price-to-earnings ratio of 27.61, a PEG ratio of 0.90 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Wall Street Analysts Forecast Growth

NVO has been the topic of several research reports. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.